Resatorvid - Akaza Biopharma
Alternative Names: Compound(R)-(+)-5n; TAK 242; TAK-242 nanoparticle; TAK-242-NP; YAQ-005Latest Information Update: 28 May 2025
At a glance
- Originator Akaza Bioscience
- Developer Akaza Bioscience; Yaqrit
- Class Anti-inflammatories; Small molecules; Sulfonamides
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholic hepatitis; Liver failure
- No development reported Hyperammonaemia; Inborn urea cycle disorders
- Discontinued Septic shock
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Liver-failure(Prevention) in United Kingdom (IV)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Hyperammonaemia in United Kingdom (Parenteral)
- 28 Feb 2025 No recent reports of development identified for preclinical development in Inborn-urea-cycle-disorders in United Kingdom (Parenteral)